Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06184360 · ClinicalTrials.gov registry record
Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 2,079
- Enrollment target
NCT06184360: Completed study, sponsored by Novartis Pharmaceuticals.
NCT06184360 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 2,079 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06184360 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 2,079 participants
- Enrollment target
Study Summary
This was a retrospective, observational cohort study. Data were analyzed from the Intelligent Research in Sight (IRIS) registry from October 8, 2019, through November 26, 2021, with a follow-up period of 12 months following the first brolucizumab injection (index date).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,079 participants |
| Start Date | 2022-05-31 |
| Est. Completion | 2022-12-16 |
What the finished NCT06184360 record still lists
NCT06184360 is an observational study that tracks outcomes without assigning an intervention. Its 2,079 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT06184360 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06184360 about?
NCT06184360 is a clinical study titled "Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)". This was a retrospective, observational cohort study. Data were analyzed from the Intelligent Research in Sight (IRIS) registry from October 8, 2019, through November 26, 2021, with a follow-up period of 12 months following the first brolucizumab injection (index date).
What is the current status of trial NCT06184360?
This trial is currently completed. The enrollment target is 2,079 participants. The study started on 2022-05-31. Estimated completion is 2022-12-16.
Who is sponsoring clinical trial NCT06184360?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04373564 · 2,076 participants · Phase 4
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
- NCT00588068 · 2,070 participants
Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome
- NCT06666192 · 2,067 participants · NA
The Ohio State University (OSU) SCREEN Community Program
- NCT07168993 · 2,063 participants · NA
Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI